Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

Fcγ receptors as regulators of immune responses

Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · see citing works

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752 · see citing works

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

Wenzel, S. E., Ford, L., Pearlman, D. S., Spector, S. L., Sher, L., Skobieranda, F. G., Wang, L., Kirkesseli, S., Rocklin, R. E., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,311 · see citing works

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075 · see citing works

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983 · see citing works

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978 · see citing works

Antibody Pharmacokinetics and Pharmacodynamics

Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909 · see citing works

Properties of mouse and human IgG receptors and their contribution to disease models

Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 869 · see citing works

Rituximab: Mechanism of Action

Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 788 · see citing works

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

Pfreundschuh, M. G. (2004) · Blood · doi:10.1182/blood-2003-06-2095 · Cited by 718 · see citing works

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 636 · see citing works

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

Teeling, J. L., Mackus, W. J. M., Wiegman, L., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S. B., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609 · see citing works

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G. M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 602 · see citing works

CD20: a regulator of cell-cycle progression of B lymphocytes

Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 598 · see citing works

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

Gaetano, N. D., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 574 · see citing works

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Cunningham, D., Hawkes, E. A., Jack, A., Qian, W., Smith, P., Mouncey, P. R., Pocock, C., Ardeshna, K. M., Radford, J. A., McMillan, A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60313-x · Cited by 561 · see citing works

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S., Miranda, P. C., Pazdur, J., Bae, S.-C., PALMER, W. R., Zrubek, J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 540 · see citing works

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence‐Bruckler, I., Maloney, D. G., Czuczman, M. S., Green, D., Rosenberg, J., McLaughlin, P. J., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526 · see citing works

From the bench to the bedside: ways to improve rituximab efficacy

Cartron, G., Watier, H., Golay, J., & Solal‐Céligny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 521 · see citing works

Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)

Milgrom, H., Berger, W. L., Nayak, A. S., Gupta, N., Pollard, S. J., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · PEDIATRICS · doi:10.1542/peds.108.2.e36 · Cited by 521 · see citing works

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

Ordás, Í., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 497 · see citing works

Clinical Pharmacokinetics of Cyclophosphamide

de Jonge, M. E., Huitema, A. D. R., Rodenhuis, S., & Beijnen, J. H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00003 · Cited by 447 · see citing works

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434 · see citing works

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

Idusogie, E. E., Presta, L. G., Gazzano, H., Tótpál, K., Wong, P. Y., Ultsch, M. H., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424 · see citing works

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 423 · see citing works

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Klein, C., Lammens, A., Schäfer, W., Georges, G. J., Schwaiger, M., Mössner, E., Hopfner, K., Umaña, P., & Niederfellner, G. J. (2013) · mAbs · doi:10.4161/mabs.22771 · Cited by 392 · see citing works

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372 · see citing works

Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia

Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359 · see citing works

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 329 · see citing works

Complement activation plays a key role in the side‐effects of rituximab treatment

van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., Hack, C. E., & van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327 · see citing works

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · see citing works

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thiéblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70122-0 · Cited by 304 · see citing works

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, H. T. C., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294 · see citing works

Engineered Antibodies with Increased Activity to Recruit Complement

Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano, H., Tótpál, K., Ultsch, M. H., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291 · see citing works

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Gisselbrecht, C., Schmitz, N., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Milpied, N. J., Radford, J. A., Ketterer, N., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9416 · Cited by 282 · see citing works

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M. G., Palumbo, G. A., Introna, M., & Golay, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713732 · Cited by 270 · see citing works

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

Pawluczkowycz, A. W., Beurskens, F. J. M., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262 · see citing works

Isotype and glycoform selection for antibody therapeutics

Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252 · see citing works

Mechanisms of action of CD20 antibodies.

Boross, P., & Leusen, J. H. W. (2012) · PubMed Central · Cited by 251 · see citing works

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Müller, C., Murawski, N., Wiesen, M. H. J., Held, G., Poeschel, V., Zeynalova, S., Wenger, M., Nickenig, C., Peter, N., Lengfelder, E., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380949 · Cited by 243 · see citing works

Neonatal Fc receptor and IgG-based therapeutics

Kuo, T. T., & Aveson, V. G. (2011) · mAbs · doi:10.4161/mabs.3.5.16983 · Cited by 236 · see citing works

CD20‐mediated apoptosis: signalling through lipid rafts

Deans, J. P., Li, H., & Polyak, M. J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01495.x · Cited by 235 · see citing works

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 231 · see citing works

A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone

Taskinen, M., Karjalainen‐Lindsberg, M., Nyman, H., Eerola, L.-M., & Leppä, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0778 · Cited by 211 · see citing works

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

Beers, S. A., Chan, H. T. C., French, R. R., Cragg, M. S., & Glennie, M. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.001 · Cited by 209 · see citing works

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D. C., & Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 208 · see citing works

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000303 · Cited by 200 · see citing works

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 196 · see citing works

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement

Wang, S., Racila, E. V., Taylor, R. P., & Weiner, G. J. (2007) · Blood · doi:10.1182/blood-2007-02-074716 · Cited by 193 · see citing works

Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials

Wang, D. D., Zhang, S., Zhao, H., Men, A. Y., & Parivar, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337512 · Cited by 192 · see citing works

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Salles, G., Morschhauser, F., Lamy, T., Milpied, N. J., Thiéblemont, C., Tilly, H., Bieska, G., Asikanius, E., Carlile, D. J., Birkett, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404368 · Cited by 187 · see citing works

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, H. T. C., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177 · see citing works

Rituximab

Keating, G. M. (2010) · Drugs · doi:10.2165/11201110-000000000-00000 · Cited by 176 · see citing works

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172 · see citing works

A Guide to Rational Dosing of Monoclonal Antibodies

Bai, S., Jorga, K. M., Xin, Y., Jin, D., Zheng, Y., Damico‐Beyer, L. A., Gupta, M., Tang, M. T., Allison, D. E., Lu, D., et al. (2012) · Clinical Pharmacokinetics · doi:10.2165/11596370-000000000-00000 · Cited by 165 · see citing works

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Kahl, C., Storer, B. E., Sandmaier, B. M., Mielcarek, M. B., Maris, M. B., Blume, K. G., Niederwieser, D. W., Chauncey, T. R., Forman, S. J., Agura, E. D., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078592 · Cited by 161 · see citing works

In vivoTargeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

Macor, P., Tripodo, C., Zorzet, S., Piovan, E., Bossi, F., Marzari, R., Amadori, A., & Tedesco, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1811 · Cited by 150 · see citing works

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Sehn, L. H., Assouline, S. E., Stewart, D. A., Mangel, J. E., Gascoyne, R. D., Fine, G. D., Lasserre, S., Carlile, D. J., & Crump, M. (2012) · Blood · doi:10.1182/blood-2012-02-408773 · Cited by 147 · see citing works

Monoclonal antibodies in neuro-oncology

Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 144 · see citing works

Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells

Beum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J. M., Engelberts, P. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101189 · Cited by 140 · see citing works

Novel CD20 monoclonal antibodies for lymphoma therapy

Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-64 · Cited by 140 · see citing works

Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Rahman, A., Carmichael, D. C., Harris, M. H., & Roh, J. K. (1986) · PubMed · Cited by 133 · see citing works

CD20: a gene in search of a function.

Riley, J. K., & Sliwkowski, M. X. (2000) · PubMed · Cited by 132 · see citing works

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Czuczman, M. S., Fayad, L., Delwail, V., Cartron, G., Jacobsen, E. D., Kuliczkowski, K., Link, B. K., Pinter‐Brown, L. C., Radford, J. A., Hellmann, A. R., et al. (2012) · Blood · doi:10.1182/blood-2011-09-378323 · Cited by 126 · see citing works

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Rubenstein, J. L., Li, J., Chen, L., Advani, R. H., Drappatz, J., Gerstner, E. R., Batchelor, T. T., Krouwer, H. G. J., Hwang, J. Q., Auerback, G. M., et al. (2012) · Blood · doi:10.1182/blood-2012-07-440974 · Cited by 123 · see citing works

Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders

Gordan, L., Grow, W. B., Pusateri, A., Douglas, V. K., Mendenhall, N. P., & Lynch, J. W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.171 · Cited by 121 · see citing works

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

Beurskens, F. J. M., Lindorfer, M. A., Farooqui, M. Z. H., Beum, P. V., Engelberts, P. J., Mackus, W. J. M., Parren, P. W. H. I., Wiestner, A. U., & Taylor, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103693 · Cited by 119 · see citing works

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

Jäger, U., Fridrik, M., Zeitlinger, M. A., Heintel, D., Hopfinger, G., Burgstaller, S., Mannhalter, C., Oberaigner, W., Porpaczy, E. A., Skrabs, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.059246 · Cited by 111 · see citing works

Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats

Kagan, L., Turner, M. R., Balu‐Iyer, S. V., & Mager, D. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0578-3 · Cited by 105 · see citing works

Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies

Muller, P., & Brennan, F. R. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 104 · see citing works

Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer

Nelson, R. L., Dyke, R. W., & Root, M. A. (1980) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(80)80003-x · Cited by 103 · see citing works

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

Bologna, L., Gotti, E., Roit, F. D., Intermesoli, T., Rambaldi, A., Introna, M., & Golay, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202645 · Cited by 99 · see citing works

Fc RIIIA and Fc RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

Carlotti, E., Palumbo, G. A., Oldani, E., Tibullo, D., Salmoiraghi, S., Rossi, A., Golay, J., Pulsoni, A., Foà, R., & Rambaldi, A. (2007) · Haematologica · doi:10.3324/haematol.11288 · Cited by 96 · see citing works

Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma

Harjunpää, A., Wiklund, T. A., Collan, J., Janes, R., Rosenberg, J., Lee, D., Grillo-López, A. J., & Meri, S. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099335 · Cited by 92 · see citing works

Pharmacokinetic Behavior of Rituximab

Regazzi, M. B., Iacona, I., Avanzini, M. A., Arcaini, L., Merlini, G., Perfetti, V., Zaja, F. F., Montagna, M., Morra, E., & Lazzarino, M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184162.60197.c1 · Cited by 92 · see citing works

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

Cartron, G., Trappe, R. U., Solal‐Céligny, P., & Hallek, M. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1292 · Cited by 84 · see citing works

Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice

Deng, R., Meng, Y. G., Hoyte, K., Lutman, J., Lu, Y., Iyer, S., DeForge, L. E., Theil, F., Fielder, P. J., & Prabhu, S. (2012) · mAbs · doi:10.4161/mabs.4.1.18543 · Cited by 83 · see citing works

Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

Li, J., Zhi, J., Wenger, M., Valente, N., Dmoszyńska, A., Robak, T., Mangat, R., Joshi, A., & Visich, J. E. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011430506 · Cited by 79 · see citing works

Molecular mechanisms regulating CD19, CD20 and CD22 gene expression

Kehrl, J. H., Riva, A., Wilson, G. L., & Thévenin, C. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90273-9 · Cited by 78 · see citing works

Setting the stage for biosimilar monoclonal antibodies

Schneider, C. K., Vleminckx, C., Gravanis, I., Ehmann, F., Trouvin, J., Weise, M., & Thirstrup, S. (2012) · Nature Biotechnology · doi:10.1038/nbt.2447 · Cited by 77 · see citing works

Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab

Pels, H., Schulz, H., Manzke, O., Hom, E., Thall, A. D., & Engert, A. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1019999830455 · Cited by 70 · see citing works

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

Ahlgrimm, M., Pfreundschuh, M. G., Kreuz, M., Regitz, E., Preuss, K., & Bittenbring, J. T. (2011) · Blood · doi:10.1182/blood-2011-04-346411 · Cited by 69 · see citing works

Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies

Lejeune, J., Thibault, G., Ternant, D., Cartron, G., Watier, H., & Ohresser, M. C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4118 · Cited by 65 · see citing works

Lymphatic Absorption Is the Primary Contributor to the Systemic Availability of Epoetin Alfa following Subcutaneous Administration to Sheep

McLennan, D. N., Porter, C. J. H., Edwards, G. A., Martin, S. W., Heatherington, A. C., & Charman, S. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078790 · Cited by 56 · see citing works

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

Aue, G., Lindorfer, M. A., Beum, P. V., Pawluczkowycz, A. W., Vire, B., Hughes, T., Taylor, R. P., & Wiestner, A. U. (2009) · Haematologica · doi:10.3324/haematol.2009.012484 · Cited by 50 · see citing works

Structural Difference in the Complement Activation Site of Human IgG1 and IgG3

Michaelsen, T. E., Sandlie, I., Bratlie, D. B., Sandin, R., & Ihle, Ø. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02338.x · Cited by 47 · see citing works

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

Carella, A. M., Souza, C. A. D., Luminari, S., Marcheselli, L., Chiappella, A., Rocco, A. D., Cesaretti, M., Rossi, A., Rigacci, L., Gaïdano, G., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.691482 · Cited by 45 · see citing works

In vivoModel of Follicular Lymphoma Resistant to Rituximab

Dalle, S., Dupire, S., Manquat, S. B., Reslan, L., Pleșa, A., & Dumontet, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1685 · Cited by 33 · see citing works

Novel targeted therapies for autoimmunity

Clair, E. W. S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.09.008 · Cited by 31 · see citing works

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

Yokoyama, H., Lundqvist, A., Su, S., & Childs, R. W. (2010) · Blood · doi:10.1182/blood-2010-06-291104 · Cited by 29 · see citing works

Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics

Harrold, J. M., Straubinger, R. M., & Mager, D. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2432 · Cited by 29 · see citing works

Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Pfreundschuh, M. G., Zeynalova, S., Poeschel, V., Haenel, M., Schmitz, N., Ho, A. D., Reiser, M., Loeffler, M., & Schubert, J. E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8508 · Cited by 29 · see citing works

Lepidopteran cells, an alternative for the production of recombinant antibodies?

Cerutti, M., & Golay, J. (2012) · mAbs · doi:10.4161/mabs.19942 · Cited by 28 · see citing works

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death

Golay, J., Bologna, L., André, P., Buchegger, F., Mach, J. P., Boumsell, L., & Introna, M. (2010) · Blood · doi:10.1182/blood-2010-06-289736 · Cited by 27 · see citing works

At diagnosis, diffuse large B ‐cell lymphoma patients show impaired rituximab‐mediated NK ‐cell cytotoxicity

Danielou‐Lazareth, A., Henry, G., Géromin, D., Khaznadar, Z., Brière, J., Tamouza, R., Cayuela, J., Thiéblemont, C., Toubert, A., & Dulphy, N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242733 · Cited by 24 · see citing works

Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma

Ternant, D., Cartron, G., Hénin, É., Tod, M. M., Girard, P., & Paintaud, G. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04125.x · Cited by 24 · see citing works

Monoclonal antibody (mAb)-based cancer therapy

Lindorfer, M. A., Wiestner, A. U., Zent, C. S., & Taylor, R. P. (2012) · OncoImmunology · doi:10.4161/onci.20368 · Cited by 23 · see citing works

Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).

Kahl, B. S., Williams, M. E., Hong, F., Gascoyne, R. D., & Horning, S. J. (2007) · Blood · doi:10.1182/blood.v110.11.3420.3420 · Cited by 17 · see citing works

Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma.

Yin, A., Li, J., Hurst, D. W., & Visich, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13108 · Cited by 16 · see citing works

Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin's Lymphoma

Martin, P., Furman, R. R., Coleman, M., & Leonard, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1085 · Cited by 16 · see citing works

A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment

Salar, A., Bouabdallah, R., McIntyre, C., Sayyed, P. Z., & Bittner, B. (2010) · Blood · doi:10.1182/blood.v116.21.2858.2858 · Cited by 12 · see citing works

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Davies, A. J., Merli, F., Mihaljevik, B., Siritanaratkul, N., Solal‐Céligny, P., Boehnke, A., Berge, C., McIntyre, C., Barrett, M., & Macdonald, D. A. (2012) · Blood · doi:10.1182/blood.v120.21.1629.1629 · Cited by 8 · see citing works

Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)

Salar, A., Avivi, I. M., Larouche, J.-F., Janíková, A., Pereira, J. C., Brewster, M., Catalani, O., McIntyre, C., Sayyed, P. Z., & Haynes, A. (2012) · Blood · doi:10.1182/blood.v120.21.1641.1641 · Cited by 8 · see citing works

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Assouline, S. E., Buccheri, V., Delmer, A. J., Doelken, G., Gaïdano, G., McIntyre, C., Brewster, M., Hourcade‐Potelleret, F., Sayyed, P. Z., & Badoux, X. C. A. (2012) · Blood · doi:10.1182/blood.v120.21.1637.1637 · Cited by 6 · see citing works

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Tobinai, K., Klein, C., Oya, N., & Fingerle‐Rowson, G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0451-1 · Cited by 186 · see citing works

Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models

Wu, Y. T., Zhong, L., & Geng, J. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.12.002 · Cited by 160 · see citing works

Anti-CD20 monoclonal antibodies: reviewing a revolution

Casan, J. M. L., Wong, J., Northcott, M., & Opat, S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1508624 · Cited by 135 · see citing works

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

Tout, M., Casasnovas, O., Meignan, M. A., Lamy, T., Morschhauser, F., Salles, G., Gyan, E., Haïoun, C., Mercier, M., Feugier, P., et al. (2017) · Blood · doi:10.1182/blood-2016-10-744292 · Cited by 98 · see citing works

Effects of rituximab therapy on B cell differentiation and depletion

Bergantini, L., d’Alessandro, M., Cameli, P., Vietri, L., Vagaggini, C., Perrone, A., Sestini, P., Frediani, B., & Bargagli, E. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-04996-7 · Cited by 95 · see citing works

Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology

Munnink, T. H. O., Henstra, M. J., Segerink, L., Movig, K. L. L., & Brummelhuis-Visser, P. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.211 · Cited by 91 · see citing works

Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

Rossi, J., Céballos, P., & Lu, Z. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0379-3 · Cited by 88 · see citing works

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Kim, W. S., Buske, C., Ogura, M., Jurczak, W. J., Sancho, J., Zhavrid, E. A., Kim, J. S., Hernández‐Rivas, J., Prokharau, A., Vasilică, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30120-5 · Cited by 77 · see citing works

A comprehensive review of the advances in neuromyelitis optica spectrum disorder.

Siriratnam, P., Huda, S., Butzkueven, H., van der Walt, A., Jokubaitis, V., & Monif, M. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103465 · Cited by 75 · see citing works

Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development

Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics &amp; Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69 · see citing works

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

Davies, A. J., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P. J., Rule, S. A., Rummel, M., McIntyre, C., Smith, R. B. W., & Badoux, X. C. A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0610-z · Cited by 67 · see citing works

Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review

Visentini, M., Tinelli, C., Colantuono, S., Monti, M., Ludovisi, S., Gragnani, L., Mitrevski, M., Ranieri, J., Fognani, E., Piluso, A., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.05.013 · Cited by 65 · see citing works

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions

Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 66 · see citing works

Antibody-mediated rejection after lung transplantation

Bery, A. I., & Hachem, R. R. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.86 · Cited by 62 · see citing works

Monoclonal Antibodies as Neurological Therapeutics

Gklinos, P., Papadopoulou, M., Stanulović, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 62 · see citing works

Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy

Fogueri, U., Cheungapasitporn, W., Bourne, D. W. A., Fervenza, F. C., & Joy, M. S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018803587 · Cited by 60 · see citing works

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Collongues, N., Ayme‐Dietrich, E., Monassier, L., & Seze, J. D. (2019) · Drugs · doi:10.1007/s40265-018-1039-7 · Cited by 60 · see citing works

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome

Rožman, S., Grabnar, I., Novaković, S., Mrhar, A., & Novaković, B. J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13271 · Cited by 58 · see citing works

Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?

Worch, J., Makarova, O., & Burkhardt, B. (2015) · Cancers · doi:10.3390/cancers7010305 · Cited by 57 · see citing works

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers

Paci, A., Desnoyer, A., Delahousse, J., Blondel, L., Maritaz, C., Chaput, N., Mir, O., & Broutin, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.005 · Cited by 57 · see citing works

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica

Collongues, N., & Seze, J. D. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616632653 · Cited by 55 · see citing works

Rituximab for immunologic renal disease: What the nephrologist needs to know

Kronbichler, A., Windpessl, M., Pieringer, H., & Jayne, D. R. W. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.007 · Cited by 55 · see citing works

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Ferreri, A. J. M., Calimeri, T., Conte, G. M., Cattaneo, D., Fallanca, F., Ponzoni, M., Scarano, E., Curnis, F., Nonis, A., Lopedote, P., et al. (2019) · Blood · doi:10.1182/blood.2019000633 · Cited by 54 · see citing works

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Teisseyre, M., Crémoni, M., Boyer‐Suavet, S., Crépin, T., Benzaken, S., Zorzi, K., Esnault, V. L. M., Brglez, V., & Seitz‐Polski, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738788 · Cited by 53 · see citing works

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

Hartinger, J. M., Krátký, V., Hrušková, Z., Slanař, O., & Tesař, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024068 · Cited by 52 · see citing works

Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

Taylor, R. P., & Lindorfer, M. A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092684 · Cited by 48 · see citing works

Antibody-Mediated Rejection in Lung Transplantation

Kulkarni, H. S., Bemiss, B., & Hachem, R. R. (2015) · Current Transplantation Reports · doi:10.1007/s40472-015-0074-5 · Cited by 44 · see citing works

Anti-CD20 Blocker Rituximab in Kidney Transplantation

Sood, P., & Hariharan, S. (2017) · Transplantation · doi:10.1097/tp.0000000000001849 · Cited by 43 · see citing works

Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model

Cao, Y., & Jusko, W. J. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9374-0 · Cited by 42 · see citing works

Extracellular Vesicles: New Players in Lymphomas

Navarro‐Tableros, V., Gomez, Y., Camussi, G., & Brizzi, M. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010041 · Cited by 38 · see citing works

A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies

Valton, J., Guyot, V., Boldajipour, B. A., Sommer, C., Pertel, T., Juillerat, A., Duclert, A., Sasu, B. J., Duchateau, P. N., & Poirot, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-27264-w · Cited by 33 · see citing works

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

Candelaria, M., Gonzalez, D., Delamain, M. T., Bär, D., Beniwal, S. K., Dasappa, L., Flores, D. H., Querol, J. M., Guan, T. S., Lipatov, O. N., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633632 · Cited by 33 · see citing works

Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

Fragoso, Y. D., Adoni, T., Brooks, J. B. B., Finkelsztejn, A., da Gama, P. D., Grzesiuk, A. K., Marques, V. D., Parolin, M. K. F., Sato, H. K., Varela, D., et al. (2018) · Neurology and Therapy · doi:10.1007/s40120-018-0110-3 · Cited by 30 · see citing works

Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review

Bellan, M., Patrucco, F., Barone‐Adesi, F., Gavelli, F., Castello, L. M., Nerviani, A., Andréoli, L., Cavagna, L., Pirisi, M., & Sainaghi, P. P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102453 · Cited by 30 · see citing works

Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series

Xiong, A., Yang, G., Song, Z., Chen, X., Deng, L., Yu, S., He, L., Zhang, L., Guo, Z., & Shuai, S. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286421998918 · Cited by 28 · see citing works

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

McGovern, D., McClure, M., Coates, M., Bond, S. J., Pero, M. M. D., Mynard, K., Lee, J., Smith, R., Jayne, D. R. W., Clatworthy, M. R., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083277 · Cited by 27 · see citing works

Inflammation Causes Resistance to Anti-CD20–Mediated B Cell Depletion

Laws, L. H., Parker, C. E., Cherala, G., Koguchi, Y., Waisman, A., Slifka, M. K., Oberbarnscheidt, M. H., Obhrai, J. S., Yeung, M. Y., & Riella, L. V. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13902 · Cited by 24 · see citing works

Determination of the Serum Concentrations of the Monoclonal Antibodies Bevacizumab, Rituximab, and Panitumumab Using Porous Membranes Containing Immobilized Peptide Mimotopes

Berwanger, J. D., Tan, H. Y., Jokhadze, G., & Bruening, M. L. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04903 · Cited by 24 · see citing works

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

McClure, M., Gopaluni, S., Wason, J. M. S., Henderson, R. B., van Maurik, A., Savage, C. O. S., Pusey, C. D., Salama, A. D., Lyons, P., Lee, J., et al. (2023) · Trials · doi:10.1186/s13063-023-07218-y · Cited by 24 · see citing works

Biological Drugs in Guillain-Barré Syndrome: An Update

Motamed-Gorji, N., Matin, N., Tabatabaie, O., Pavone, P., Romano, C., Falsaperla, R., & Vitaliti, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666161213114904 · Cited by 23 · see citing works

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis

Lim, S. H., Kim, K., & Choi, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081265 · Cited by 24 · see citing works

Current evidence of rituximab in the treatment of multiple sclerosis

Techa-angkoon, P., Siritho, S., Tisavipat, N., & Suansanae, T. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104729 · Cited by 19 · see citing works

Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy

Tarantelli, C., Wald, D. N., Munz, N., Spriano, F., Bruscaggin, A., Cannas, E., Cascione, L., Gaudio, E., Arribas, A. J., Manjappa, S., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284197 · Cited by 19 · see citing works

Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review

Regazzi, M. B., Golay, J., & Molinaro, M. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000681 · Cited by 19 · see citing works

Rituximab resistance in ITP and beyond

Xiao, Z., & Murakhovskaya, I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1215216 · Cited by 18 · see citing works

A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis

Hartinger, J. M., Šíma, M., Hrušková, Z., Pilková, A., Krátký, V., Ryšavá, R., Jančová, E., Bobek, D., Douša, J., Francová, I., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116655 · Cited by 17 · see citing works

Anti-CD20 Monoclonal Antibodies in Chronic Lymphocytic Leukemia: From Uncertainties to Promises

Bagacean, C., Zdrenghea, M., Tempescul, A., Cristea, V., & Renaudineau, Y. (2016) · Immunotherapy · doi:10.2217/imt-2015-0015 · Cited by 17 · see citing works

Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome

Chen, Y., Shen, Q., Dong, M., Xiong, Y., Xu, H. M., & Li, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.725665 · Cited by 16 · see citing works

Targeted Treatments for Myasthenia Gravis in Children and Adolescents

Ramdas, S., Paínho, T., Vanegas, M., Famili, D. T., Lim, M. J., & Jungbluth, H. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00649-3 · Cited by 16 · see citing works

Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?

Golay, J. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.002 · Cited by 15 · see citing works

The Influence of Different Disease States on Rituximab Pharmacokinetics

Wang, X., Du, W., Zhang, X., & Li, P. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200719004035 · Cited by 14 · see citing works

Rituximab by subcutaneous route

Solal-Celigny, P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1024651 · Cited by 13 · see citing works

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma

Merli, M., Ferrario, A., Maffioli, M., Arcaini, L., & Passamonti, F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1038342 · Cited by 13 · see citing works

Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency – Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens

Zdziarski, P., & Gamian, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01559 · Cited by 12 · see citing works

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients

Baker, B., Schaeffler, B. A., Hirman, J., Hompesch, M., Pederson, S. M., & Smith, J. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.217 · Cited by 12 · see citing works

The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer

Thomas, J. W., Torok, M. A., Agrawal, K., Pfau, T., Vu, T. T., Lyberger, J. M., Chang, H., Castillo, A. M. M., Chen, M., Remaily, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137066 · Cited by 12 · see citing works

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring

Monteiro, J., Fernandes, A., Tato, D. G., Moreira, E., Ribeiro, R. J. T., Reguengo, H., Gonçalves, J., & Fresco, P. (2025) · Cancers · doi:10.3390/cancers17193262 · Cited by 11 · see citing works

A compartment model for subcutaneous injection of monoclonal antibodies

Zhong, X., Liu, Y., & Ardekani, A. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123687 · Cited by 11 · see citing works

Challenges in realizing therapeutic antibody biosensing

Nagata, M., Wilson, E. D., Ikebukuro, K., & Sode, K. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.003 · Cited by 10 · see citing works

Interventional nuclear medicine: a focus on radioguided intervention and surgery

Rietbergen, D. D. D., van Oosterom, M. N., KleinJan, G. H., Brouwer, O. R., Valdés-Olmos, R. A., van Leeuwen, F. W. B., & Buckle, T. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03286-6 · Cited by 10 · see citing works

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

Janíková, A., Bortlíček, Z., Campr, V., Kopálová, N., Benešová, K., Hamouzova, J., Belada, D., Procházka, V., Pytlík, R., Vokurka, S., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1079313 · Cited by 10 · see citing works

No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant

King, A. C., Kabel, C. C., Pappacena, J. J., Stump, S. E., & Daley, R. J. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019836775 · Cited by 10 · see citing works

Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city

Ashtari, F., Mehdipour, R., Shaygannejad, V., & Mansourian, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.06.013 · Cited by 10 · see citing works

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

Castillo, J. J., Gustine, J. N., Keezer, A., Meid, K., Flynn, C. A., Dubeau, T. E., Chan, G., Chen, J. G., Demos, M. G., Guerrera, M. L., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25712 · Cited by 10 · see citing works

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab

Marcacci, G., Fiorentino, G., Volzone, F., Falcone, U., Parrella, R., Donnarumma, D., D’Ovidio, S., Annunziata, A., Micallo, G., Portella, G., et al. (2021) · Infectious Agents and Cancer · doi:10.1186/s13027-021-00376-1 · Cited by 10 · see citing works

Rituximab in the Treatment of Non-Infectious Uveitis: A Review

Cao, H., & Ma, X. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s477708 · Cited by 9 · see citing works

State of the Evidence: Drug Removal via Apheresis

Binns, T. C., Sostin, N. K., & Tormey, C. A. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.12.003 · Cited by 8 · see citing works

Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus

Tian, Y., Enioutina, E. Y., Brunner, H. I., Vinks, A. A. T. M. M., & Sherwin, C. M. T. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0426-z · Cited by 9 · see citing works

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01

Huang, Y., Zhang, L., Karuna, S., Andrew, P., Juraska, M., Weiner, J. A., Angier, H. E., Morgan, E., Azzam, Y., Swann, E. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43399-5 · Cited by 9 · see citing works

Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy

Morano, A., Iannone, L. F., Palleria, C., Fanella, M., Giallonardo, A. T., Sarro, G. D., Russo, E., & Bonaventura, C. D. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1541349 · Cited by 8 · see citing works

Development of a time-resolved fluoroimmunoassay for rituximab and its application to therapeutic drug monitoring

Kao, S., Liu, X., Jin, J., Zhang, L., Shen, T., Wu, J., Qin, Y., Zhou, X., Zhao, X., Wang, L., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120142 · Cited by 7 · see citing works

Rheumatoid granulomatous disease and pachymeningitis successfully treated with rituximab

Moeyersoons, A., Verschueren, P., Tousseyn, T., & Langhe, E. D. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1375193 · Cited by 7 · see citing works

Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2

Liu, S., Huang, H., Chen, R., Wang, Z., Guan, Y.-P., Chen, P., Fang, X., Chen, Z., Guan, S., Zhu, X., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0479-2 · Cited by 7 · see citing works

Sex as decisive variable in lymphoid neoplasms—an update

Vanura, K. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100001 · Cited by 8 · see citing works

Is rituximab sub‐optimally dosed in indolent B cell lymphoma?

Sawalha, Y., Rouphail, B., Jia, X., Dean, R. M., Hill, B. T., Jagadeesh, D., Pohlman, B. L., & Smith, M. R. (2016) · British Journal of Haematology · doi:10.1111/bjh.14114 · Cited by 7 · see citing works

Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience

Hu, M., Zhang, T., Liu, B., Guo, Q., Zhao, B. Q., Lin, J., Lv, Z., & Wang, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1567886 · Cited by 6 · see citing works

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

Liu, D., Zhou, Z., Wang, M., Nie, S., Li, J., Hu, B., He, W., Wang, G., & Ai, J. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02437-4 · Cited by 6 · see citing works

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes

Liu, S., Wang, Z., Chen, R., Huang, H., Wang, X., Chen, P., Guan, Y., Fang, X., Guan, S., Huang, H., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13186 · Cited by 6 · see citing works

Obinutuzumab for the management of immune-mediated glomerular diseases

Rossi, G. M., Baier, E., & Vaglio, A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf021 · Cited by 6 · see citing works

Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome

Rekeland, I. G., Fluge, Ø., Alme, K., Risa, K., Sørland, K., Mella, O., de Vries, A., & Schjøtt, J. D. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.019 · Cited by 6 · see citing works

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Lavezzi, S. M., de Jong, J., Neyens, M., Cramer, P., Demırkan, F., Fraser, G. A. M., Bartlett, N. L., Dilhuydy, M., Loscertales, J., Avigdor, A., et al. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2605-8 · Cited by 6 · see citing works

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL

D’Rozario, J., & Bennett, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719844697 · Cited by 6 · see citing works

Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology

Khandelwal, K., Jajoo, V., Bajpai, K., Madke, B., Prasad, R., Wanjari, M. B., Munjewar, P. K., & Taksande, A. B. (2023) · Cureus · doi:10.7759/cureus.40734 · Cited by 6 · see citing works

Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats

Otani, Y., Yonezawa, A., Tsuda, M., Imai, S., Ikemi, Y., Nakagawa, S., Omura, T., Nakagawa, T., Yano, I., & Matsubara, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169588 · Cited by 6 · see citing works

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP

Kelen, K., Horváth, O. N., Kis, É., Mikes, B., Sallay, P., Prohászka, Z., Szabo, A. J., & Reusz, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814389 · Cited by 5 · see citing works

Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases

Larrosa-García, M., Agraz, I., Sanz-Martínez, M. T., Bury, R., Martínez‐Gallo, M., Colobrán, R., García, S. G., Soler, M. J., Hernández-González, M., & Ronsano, J. B. M. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001353 · Cited by 5 · see citing works

In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure

Payandeh, Z., Rajabibazl, M., Mortazavi, Y., & Rahimpour, A. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9654-9 · Cited by 5 · see citing works

Therapeutic Monoclonal Antibodies as Immunomodulators and Anti-Cancer Agents: Development, Evidence of Efficacy, Mechanisms of Actions, Adverse Effects

Niehues, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-68038-5_20 · Cited by 5 · see citing works

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia

Kalaycio, M. E., & Hill, B. T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s68770 · Cited by 5 · see citing works

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCAassociated vasculitis (COMBIVAS): design of the study protocolPreprint

McClure, M., Gopaluni, S., Wason, J. M. S., Henderson, R. B., van Maurik, A., Savage, C. O. S., Pusey, C. D., Salama, A. D., Lyons, P., Lee, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2138639/v1 · Cited by 5 · see citing works

Obinutuzumab in kidney transplantation: Past, present, and future

Favi, E., & Morabito, M. (2025) · World Journal of Transplantation · doi:10.5500/wjt.v15.i4.108982 · Cited by 4 · see citing works

Therapeutic applications and strategies of neurobiomarkers in neurological disorders: A narrative review

Kumar, P., Chaudhary, B., Devi, S., Dubey, G., Chatterjee, A., Sharma, D., & Gupta, M. M. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100113 · Cited by 4 · see citing works

Extracellular vesicles: a potential new player in antibody-mediated rejection in lung allograft recipients

Bansal, S., Arjuna, A., Franz, B. J., Guerrero-Alba, A., Canez, J., Fleming, T. P., Rahman, M. A., Hachem, R. R., & Mohanakumar, T. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1248987 · Cited by 4 · see citing works

Antibody-Mediated Rejection: Mechanisms, Pathology, and Therapeutics

Chakravorty, S., Aryal, S., Cochrane, A. B., & Nathan, S. D. (2024) · Current Pulmonology Reports · doi:10.1007/s13665-024-00349-w · Cited by 4 · see citing works

Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody

Ahmadpoor, P., Aglaé, C., Garo, F., Cariou, S., Renaud, S., Reboul, P., & Moranne, O. P. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03020-7 · Cited by 4 · see citing works

D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer

Mitri, N., Rahme, K., Fracasso, G., & Ghanem, E. (2021) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ac2747 · Cited by 4 · see citing works

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives

Moog, P., & Thuermel, K. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79080 · Cited by 4 · see citing works

Obinutuzumab in the treatment of idiopathic refractory membranous nephropathy: an observational case series

Zhao, X., Chang, X., Wang, Y. L., CHEN, D., Yu, M., Zhao, J., Zhu, H., Mao, Y., & Juan, C. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1704970 · Cited by 3 · see citing works

Pharmacokinetics of rituximab and its clinical use: Thought for the best use?

Cartron, G., Blasco, H., Paintaud, G., Watier, H., & Guellec, C. B. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.09.004 · Cited by 122 · see citing works

Pharmacokinetic Properties of Rituximab

Rodriguez, J., & Gutierrez, A. M. (2008) · Reviews on Recent Clinical Trials · doi:10.2174/157488708783330495 · Cited by 21 · see citing works

Monoclonal Antibodies

Bai, S., Deng, R., Xiang, H., Gupta, M., Musib, L. C., Anand, B. S., & Lum, B. L. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_30 · Cited by 3 · see citing works

Relationship between plasma concentration and efficacy of rituximab in the patient with non-Hodgkin's lymphoma

Mori, M., Yonezawa, A., Otani, Y., Isomoto, Y., Tsuda, M., Imani, S., Kitano, T., Takaori, A. K., Hayakari, M., & Matsubara, K. (2018) · Proceedings for Annual Meeting of The Japanese Pharmacological Society · doi:10.1254/jpssuppl.wcp2018.0_po2-14-12

The Influence of Different Disease States on Rituximab Pharmacokinetics

Wang, X., Du, W., Zhang, X., & Li, P. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200719004035 · Cited by 14 · see citing works